People with multiple sclerosis (MS) are at a higher risk of developing and dying from bladder cancer than people without the neurodegenerative disorder, according to a Canadian population-based study. However, no differences were found between MS patients and unaffected individuals in terms of their risk of breast and…
Novartis has partnered with iHeartRadio to launch the first free on-demand streaming radio station dedicated to the multiple sclerosis (MS) community. Named MS Vibes, the station is focused “on popular music, educational content and relatable topics to which listeners can connect, uplift and recharge,” Leverne Marsh, vice president…
A particular type of gut microbiota-reactive immune cells, called IgA-producing B-cells, travels to the brain of multiple sclerosis (MS) patients during relapses, where they produce anti-inflammatory molecules, a study shows. The underlying mechanisms of this event and these cells’ role in MS remain largely unclear, but these…
Early and continuous use of Ocrevus (ocrelizumab) significantly slows disability progression and delays the time until wheelchair reliance in people with primary progressive multiple sclerosis (PPMS), new Phase 3 data spanning more than six years show. Findings from the ORATORIO trial, comparing immediate use with a two-year delay, support Ocrevus’…
Typing patterns in daily smartphone use show clinically relevant changes over time in people with multiple sclerosis (MS), but not among healthy individuals, a study shows. Notably, these variations often coincided with clinically meaningful changes in measures of disease activity, disability, and/or fatigue in MS patients with and without…
Patients in the early stages of multiple sclerosis with mild to moderate symptoms of depression performed worse on cognitive tests related to multitasking than on those focused on single tasks, a study has found. Notably, no such association was observed among healthy individuals, suggesting an MS-related link between mood,…
The nonprofit Autoimmune Registry (ARI) has published its first comprehensive list of autoimmune diseases, with information addressing more than 150 disorders, their subtypes, and prevalence in the U.S. This list was created in part to provide patients and scientists easy access to the latest peer-reviewed research, information on clinical…
Using a small molecule called TEPP-46 to block the non-metabolic function of the enzyme pyruvate kinase M2 (PKM2) in T-helper (Th) immune cells did not lessen disease severity and redirected inflammation and neural damage from the spinal cord to the brain in a mouse model of multiple sclerosis…
Immunic Therapeutics is seeking 60 more adults with relapsing-remitting multiple sclerosis (RRMS) to test a lower dose of IMU-838, its leading oral experimental therapy, in its ongoing Phase 2 EMPhASIS trial. The decision was based on previous trial results showing that both doses tested (30 and 45…
An autologous hematopoietic stem cell transplant (AHSCT) is more effective than Lemtrada (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study in Sweden reported. Adverse events (side effects) were more frequent with AHSCT over the first three…
Genentech’s Ocrevus (ocrelizumab) continues to be the most prescribed treatment for people with progressive forms of multiple sclerosis (MS) among U.S. neurologists, according to the latest Spherix Global Insights’ report. However, Novartis’ Mayzent (siponimod) “is beginning to close the gap” with Ocrevus among those with active secondary progressive MS…
Adults with multiple sclerosis (MS) and other neurological disorders are being recruited to take part in a 12-week clinical trial that aims to assess the health benefits of home-based tele-exercise — performed while seated — led by the Burke Neurological Institute, in New York, according to an…
MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional ability or walking speed in people with non-active progressive multiple sclerosis (MS), according to data from a Phase 3 clinical trial. Besides failing to meet the trial’s goals, the therapy was associated with inaccurate results in…
Suppressing pyruvate kinase M2 (PKM2) — an enzyme involved in cellular metabolism — in T-helper (Th) immune cells lessened myelin loss and disease severity in a mouse model of multiple sclerosis (MS). Myelin, the protective sheath around nerve fibers that helps speed transmission of signals between nerve cells, is damaged and lost…
Biogen is discontinuing the clinical development of opicinumab, its experimental treatment candidate for multiple sclerosis (MS), based on data from the Phase 2 AFFINITY clinical trial. The announcement, amid a third-quarter report, indicated that the study failed to meet both its main and secondary goals, without further details. The trial,…
Two genetic variants have been identified by researchers within a genome region previously reported to drive a 1.44-times increased risk of multiple sclerosis (MS) in a group of African Americans with European ancestry. Located in genes involved in immune responses, the variants fully explain the reported European ancestry-associated increased…
The presence of a particular gut bacterium widely used in probiotics, called Lactobacillus reuteri (L. reuteri), was sufficient to increase disease severity in a mouse model of multiple sclerosis (MS), but only in genetically susceptible animals, a recent study shows. These findings highlight the complex interactions between…
Oral administration of trehalose — a sugar molecule found in plants and fungi and reported to have neuroprotective effects — eased symptoms and halted disease progression in a mouse model of multiple sclerosis (MS). These benefits were associated with a restoration of the ability of microglia (the brain’s immune cells) to break down…
In a nationwide survey of caregiver abuse and neglect among Americans with advanced multiple sclerosis (MS), more than half of respondents reported some form of mistreatment, with psychological and financial abuse being the most common. Having a caregiver with a mental illness was the greatest risk factor for mistreatment, the survey…
Oral administration of N-acetylglucosamine (GlcNAc) — a natural simple sugar sold as a dietary supplement — prevents myelin degeneration and loss of motor function in a mouse model of multiple sclerosis (MS). Myelin, the protective sheath around nerve fibers that helps to speed transmission of signals between nerve cells, is damaged…
Low blood levels of ferritin — the main form of iron stored in cells — are significantly associated with more severe depressive symptoms and poorer quality of life in multiple sclerosis (MS) patients, a small study from Poland reports. Data showed no link between the levels of other measures of…
Older age at disease-modifying therapy (DMT) discontinuation is the main predictive factor of sustained “no evidence of disease activity” (NEDA) in people starting DMT immediately after being diagnosed with clinically isolated syndrome (CIS), according to a study in Austria. In particular, patients discontinuing DMT at age 45 or…
The National Institutes of Health (NIH) awarded a $2.3 million grant to a bioengineer at Indiana University’s Luddy School of Informatics, Computing and Engineering to improve diagnosis and treatment of autoimmune diseases, such as multiple sclerosis (MS). The project aims to find ways to detect disease-associated cells based on their ability…
Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights. Also, COVID-19 not…
After a pregnancy or childbirth, most women who went on to develop clinically isolated syndrome (CIS) did so about three years later than those who were never pregnant, a large and multicenter study reported. Multiple pregnancies or births, however, were not seen to further affect CIS onset. More research is…
Fatigue is the most impactful symptom on daily functioning in people with relapsing forms of multiple sclerosis (MS) and is more severe in patients with relapse, pain, depression, and sleep disorders, according to a U.S.-based survey. The results were based mostly on a new MS-specific tool called the Fatigue Symptoms…
AB Science’s lead candidate masitinib safely and effectively delays disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to…
Early use of Ocrevus (ocrelizumab) significantly slows shrinkage of the thalamus — a brain region involved in sensory and motor functions — in people with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), according to new analyses from three Phase 3 trials that compared immediate use with a two-year…
Most children and adolescents with pediatric-onset multiple sclerosis (POMS), especially those treated intravenously with a disease-modifying therapy (DMT), achieve no evidence of disease activity within two years of diagnosis, according to a real-life study from the U.S. Patients whose DMTs are infused into a vein (intravenous treatment) are more likely…
Remyelination — or the restoration of lost myelin, the protective sheath surrounding nerve cell fibers — in multiple sclerosis (MS) depends mainly on pre-existing oligodendrocytes (myelin-producing cells), rather than on newly-generated oligodendrocytes, according to a recent study. The data also showed that perineuronal, or satellite,…
Get regular updates to your inbox.